Literature DB >> 29207890

Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease.

Edith L Pfister1, Natalie DiNardo1, Erica Mondo2, Florie Borel3, Faith Conroy1, Cara Fraser4, Gwladys Gernoux3, Xin Han5, Danjing Hu5, Emily Johnson1,6, Lori Kennington1, PengPeng Liu5, Suzanne J Reid7, Ellen Sapp8, Petr Vodicka8,9, Tim Kuchel4, A Jennifer Morton10, David Howland11, Richard Moser12, Miguel Sena-Esteves3, Guangping Gao3, Christian Mueller3,13, Marian DiFiglia8, Neil Aronin1,14.   

Abstract

Huntington's disease (HD) is a fatal neurodegenerative disease caused by a genetic expansion of the CAG repeat region in the huntingtin (HTT) gene. Studies in HD mouse models have shown that artificial miRNAs can reduce mutant HTT, but evidence for their effectiveness and safety in larger animals is lacking. HD transgenic sheep express the full-length human HTT with 73 CAG repeats. AAV9 was used to deliver unilaterally to HD sheep striatum an artificial miRNA targeting exon 48 of the human HTT mRNA under control of two alternative promoters: U6 or CβA. The treatment reduced human mutant (m) HTT mRNA and protein 50-80% in the striatum at 1 and 6 months post injection. Silencing was detectable in both the caudate and putamen. Levels of endogenous sheep HTT protein were not affected. There was no significant loss of neurons labeled by DARPP32 or NeuN at 6 months after treatment, and Iba1-positive microglia were detected at control levels. It is concluded that safe and effective silencing of human mHTT protein can be achieved and sustained in a large-animal brain by direct delivery of an AAV carrying an artificial miRNA.

Entities:  

Keywords:  AAV; Huntington's disease; RNAi; large animal models

Mesh:

Substances:

Year:  2018        PMID: 29207890      PMCID: PMC6909722          DOI: 10.1089/hum.2017.199

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  29 in total

1.  Finding the striatum in sheep: use of a multi-modal guided approach for convection enhanced delivery.

Authors:  I M J van der Bom; R P Moser; G Gao; E Mondo; D O'Connell; M J Gounis; S McGowan; J Chaurette; N Bishop; M S Sena-Esteves; C Mueller; N Aronin
Journal:  J Huntingtons Dis       Date:  2013

2.  New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins.

Authors:  J Ko; S Ou; P H Patterson
Journal:  Brain Res Bull       Date:  2001 Oct-Nov 1       Impact factor: 4.077

3.  Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.

Authors:  Edgardo Rodriguez-Lebron; Eileen M Denovan-Wright; Kevin Nash; Alfred S Lewin; Ronald J Mandel
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

4.  Early and progressive circadian abnormalities in Huntington's disease sheep are unmasked by social environment.

Authors:  A Jennifer Morton; Skye R Rudiger; Nigel I Wood; Stephen J Sawiak; Gregory C Brown; Clive J Mclaughlan; Timothy R Kuchel; Russell G Snell; Richard L M Faull; C Simon Bawden
Journal:  Hum Mol Genet       Date:  2014-01-31       Impact factor: 6.150

5.  rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse.

Authors:  Yoko Machida; Takashi Okada; Masaru Kurosawa; Fumitaka Oyama; Keiya Ozawa; Nobuyuki Nukina
Journal:  Biochem Biophys Res Commun       Date:  2006-03-03       Impact factor: 3.575

6.  A High-Throughput Method for Direct Detection of Therapeutic Oligonucleotide-Induced Gene Silencing In Vivo.

Authors:  Andrew H Coles; Maire F Osborn; Julia F Alterman; Anton A Turanov; Bruno M D C Godinho; Lori Kennington; Kathryn Chase; Neil Aronin; Anastasia Khvorova
Journal:  Nucleic Acid Ther       Date:  2015-11-23       Impact factor: 5.486

7.  Frameless multimodal image guidance of localized convection-enhanced delivery of therapeutics in the brain.

Authors:  Imramsjah M J van der Bom; Richard P Moser; Guanping Gao; Miguel Sena-Esteves; Neil Aronin; Matthew J Gounis
Journal:  J Neurointerv Surg       Date:  2011-12-22       Impact factor: 5.836

8.  Safe and Efficient Silencing with a Pol II, but Not a Pol lII, Promoter Expressing an Artificial miRNA Targeting Human Huntingtin.

Authors:  Edith L Pfister; Kathryn O Chase; Huaming Sun; Lori A Kennington; Faith Conroy; Emily Johnson; Rachael Miller; Florie Borel; Neil Aronin; Christian Mueller
Journal:  Mol Ther Nucleic Acids       Date:  2017-04-14

9.  Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing.

Authors:  Karine Cambon; Virginie Zimmer; Sylvain Martineau; Marie-Claude Gaillard; Margot Jarrige; Aurore Bugi; Jana Miniarikova; Maria Rey; Raymonde Hassig; Noelle Dufour; Gwenaelle Auregan; Philippe Hantraye; Anselme L Perrier; Nicole Déglon
Journal:  Mol Ther Methods Clin Dev       Date:  2017-05-11       Impact factor: 6.698

10.  Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain.

Authors:  Dominik F Aschauer; Sebastian Kreuz; Simon Rumpel
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

View more
  29 in total

Review 1.  Recent advances in molecular therapies for neurological disease: triplet repeat disorders.

Authors:  Pedro Gonzalez-Alegre
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

Review 2.  The Tiny Drosophila Melanogaster for the Biggest Answers in Huntington's Disease.

Authors:  Abraham Rosas-Arellano; Argel Estrada-Mondragón; Ricardo Piña; Carola A Mantellero; Maite A Castro
Journal:  Int J Mol Sci       Date:  2018-08-14       Impact factor: 5.923

Review 3.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

4.  CaMKIIα-Positive Interneurons Identified via a microRNA-Based Viral Gene Targeting Strategy.

Authors:  Marianna K Keaveney; Bahar Rahsepar; Hua-An Tseng; Fernando R Fernandez; Rebecca A Mount; Tina Ta; John A White; Jim Berg; Xue Han
Journal:  J Neurosci       Date:  2020-11-06       Impact factor: 6.167

Review 5.  Epigenetic mechanisms of neurodegenerative diseases and acute brain injury.

Authors:  Mario J Bertogliat; Kahlilia C Morris-Blanco; Raghu Vemuganti
Journal:  Neurochem Int       Date:  2019-12-12       Impact factor: 3.921

Review 6.  Recent Advances in the Treatment of Huntington's Disease: Targeting DNA and RNA.

Authors:  Kathleen M Shannon
Journal:  CNS Drugs       Date:  2020-03       Impact factor: 5.749

Review 7.  Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.

Authors:  Jana Miniarikova; Melvin M Evers; Pavlina Konstantinova
Journal:  Mol Ther       Date:  2018-02-08       Impact factor: 11.454

Review 8.  Huntington's Disease: New Frontiers in Therapeutics.

Authors:  Ling Pan; Andrew Feigin
Journal:  Curr Neurol Neurosci Rep       Date:  2021-02-14       Impact factor: 5.081

9.  Allele-Specific Knockdown of Mutant Huntingtin Protein via Editing at Coding Region Single Nucleotide Polymorphism Heterozygosities.

Authors:  Sarah R Oikemus; Edith L Pfister; Ellen Sapp; Kathryn O Chase; Lori A Kennington; Edward Hudgens; Rachael Miller; Lihua Julie Zhu; Akanksh Chaudhary; Eric O Mick; Miguel Sena-Esteves; Scot A Wolfe; Marian DiFiglia; Neil Aronin; Michael H Brodsky
Journal:  Hum Gene Ther       Date:  2022-01       Impact factor: 5.695

Review 10.  [Gene-selective treatment approaches for Huntington's disease].

Authors:  A Mühlbäck; K S Lindenberg; C Saft; J Priller; G B Landwehrmeyer
Journal:  Nervenarzt       Date:  2020-04       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.